Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent

被引:100
作者
Ptak, Roger G. [2 ]
Gallay, Philippe A. [3 ]
Jochmans, Dirk [4 ]
Halestrap, Andrew P. [5 ]
Ruegg, Urs T. [6 ]
Pallansch, Luke A. [2 ]
Bobardt, Michael D. [3 ]
de Bethune, Marie-Pierre [4 ]
Neyts, Johan [7 ]
De Clercq, Erik [7 ]
Dumont, Jean-Maurice [1 ]
Scalfaro, Pietro [1 ]
Besseghir, Kamel [1 ]
Wenger, Roland M. [8 ]
Rosenwirth, Brigitte [9 ]
机构
[1] Forum Apres Demain, Debiopharm SA, CH-1002 Lausanne, Switzerland
[2] So Res Inst, Frederick, MD 21701 USA
[3] Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA
[4] Tibotec BVBA, B-2800 Mechelen, Belgium
[5] Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England
[6] Univ Geneva & Lausanne, Sch Pharmaceut Sci, Pharmacol Lab, CH-1211 Geneva, Switzerland
[7] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium
[8] Wenger Chemtech, CH-4125 Riehen, Switzerland
[9] Med Univ Wien, Klin Inst Virol, A-1095 Vienna, Austria
关键词
D O I
10.1128/AAC.01324-07
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Debio-025 is a synthetic cyclosporine with no immunosuppressive capacity but a high inhibitory potency against cyclophilin A (CypA)-associated cis-trans prolyl isomerase (PPIase) activity. A lack of immunosuppressive effects compared to that of cyclosporine was demonstrated both in vitro and in vivo. For three cyclosporines, the inhibitory potential against PPIase activity was quantitatively correlated with that against human immunodeficiency virus type 1 (HIV-1) replication. Debio-025 selectively inhibited the replication of HIV-1 in a CD4(+) cell line and in peripheral blood mononuclear cells: potent activity was demonstrated against clinical isolates of various HIV-1 subtypes, including isolates with multidrug resistance to reverse transcriptase and protease inhibitors. Simian immunodeficiency virus and HIV-2 strains were generally resistant to inhibition by Debio-025; however, some notable exceptions of sensitive HIV-2 clinical isolates were detected. In two-drug combination studies, additive inhibitory effects were found between Debio-025 and 19 clinically used drugs of different classes. Clinical HIV-1 isolates that are naturally resistant to Debio-025 and that do not depend on CypA for infection were identified. Comparison of the amino acid sequences of the CypA binding domain of the capsid (CA) protein from Debio-025-sensitive and -resistant HIV-1 isolates indicated that resistance was mostly associated with an H87Q/P exchange. Mechanistically, cyclosporines competitively inhibit the binding of CypA to the HIV-1 CA protein, which is an essential interaction required for early steps in HIV-1 replication. By real-time PCR we demonstrated that early reverse transcription is reduced in the presence of Debio-025 and that late reverse transcription is almost completely blocked. Thus, Debio-025 seems to interfere with the function of CypA during the progression/completion of HIV-1 reverse transcription.
引用
收藏
页码:1302 / 1317
页数:16
相关论文
共 106 条
[1]   Spontaneous mutations in the human immunodeficiency virus type 1 gag gene that affect viral replication in the presence of cyclosporins [J].
Aberham, C ;
Weber, S ;
Phares, W .
JOURNAL OF VIROLOGY, 1996, 70 (06) :3536-3544
[2]  
Andrei G, 1998, ONCOL RES, V10, P523
[3]   Susceptibilities of several clinical Varicella-zoster virus (VZV) isolates and drug-resistant VZV strains to bicyclic furano pyrimidine nucleosides [J].
Andrei, G ;
Sienaert, R ;
McGuigan, C ;
De Clercq, E ;
Balzarini, J ;
Snoeck, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (03) :1081-1086
[4]   AIDS AND RELATED SYNDROMES AS A VIRAL-INDUCED AUTOIMMUNE-DISEASE OF THE IMMUNE-SYSTEM - AN ANTI-MHC-II DISORDER - THERAPEUTIC IMPLICATIONS [J].
ANDRIEU, JM ;
EVEN, P ;
VENET, A .
AIDS RESEARCH, 1986, 2 (03) :163-174
[5]   Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics [J].
Balzarini, Jan ;
Keyaerts, Els ;
Vijgen, Leen ;
Egberink, Herman ;
De Clercq, Erik ;
Van Ranst, Marc ;
Printsevskaya, Svetlana S. ;
Olsufyeva, Eugenia N. ;
Solovieva, Svetlana E. ;
Preobrazhenskaya, Maria N. .
ANTIVIRAL RESEARCH, 2006, 72 (01) :20-33
[6]  
BARE J, 2004, KEYST S HIV PATH, P1
[7]   INHIBITION OF HUMAN-IMMUNODEFICIENCY-VIRUS REPLICATION BY NONIMMUNOSUPPRESSIVE ANALOGS OF CYCLOSPORINE-A [J].
BARTZ, SR ;
HOHENWALTER, E ;
HU, MK ;
RICH, DH ;
MALKOVSKY, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (12) :5381-5385
[8]   MOLECULAR MECHANISMS OF IMMUNOSUPPRESSION [J].
BAUMANN, G ;
ZENKE, G ;
WENGER, R ;
HIESTAND, P ;
QUESNIAUX, V ;
ANDERSEN, E ;
SCHREIER, MH .
JOURNAL OF AUTOIMMUNITY, 1992, 5 :67-72
[9]   Restriction of lentivirus in monkeys [J].
Besnier, C ;
Takeuchi, Y ;
Towers, G .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (18) :11920-11925
[10]   MODE OF ACTION OF SDZ NIM-811, A NONIMMUNOSUPPRESSIVE CYCLOSPORINE-A ANALOG WITH ACTIVITY AGAINST HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) TYPE-1 - INTERFERENCE WITH HIV PROTEIN-CYCLOPHILIN-A INTERACTIONS [J].
BILLICH, A ;
HAMMERSCHMID, F ;
PEICHL, P ;
WENGER, R ;
ZENKE, G ;
QUESNIAUX, V ;
ROSENWIRTH, B .
JOURNAL OF VIROLOGY, 1995, 69 (04) :2451-2461